Payment overview · 2025
General Payments
$455.79
22 reported records · 9 companies
Healthcare provider profile · identity verified
Jennifer Seda Ramirez, M.D.
Allopathic & Osteopathic Physicians|General Practice · ST AUGUSTINE, FL · NPI 1912971102
Verified facts
What the public records show
CMS Open Payments records show Jennifer Seda Ramirez, M.D. received $455.79 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.22 | 37.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.43 | 23.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.93 | 10.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.87 | 8.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.63 | 5.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.66 | 4.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.70 | 3.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.82 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.53 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $455.79 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $90.83 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $90.41 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $82.86 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.77 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.66 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.93 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 394 | 105 |
| Lisinopril | Lisinopril | 356 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 345 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 96 |
| Losartan Potassium | Losartan Potassium | 289 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 99 |
| Omeprazole | Omeprazole | 199 | 62 |
| Gabapentin | Gabapentin | 187 | 65 |
| Sertraline Hcl | Sertraline Hcl | 179 | 40 |
| Furosemide | Furosemide | 167 | 51 |
| Metformin Hcl | Metformin Hcl | 166 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 52 |
| Simvastatin | Simvastatin | 157 | 38 |
| Trazodone Hcl | Trazodone Hcl | 145 | 47 |
| Ozempic | Semaglutide | 143 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 39 |
| Meloxicam | Meloxicam | 123 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 35 |
| Montelukast Sodium | Montelukast Sodium | 118 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 113 | 94 |
| Carvedilol | Carvedilol | 108 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 38 |
| Alendronate Sodium | Alendronate Sodium | 103 | 27 |
| Fenofibrate | Fenofibrate | 100 | 37 |
| Alprazolam | Alprazolam | 96 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 50 |
| Ezetimibe | Ezetimibe | 91 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 27 |
| Buspirone Hcl | Buspirone Hcl | 72 | 26 |
| Ibuprofen | Ibuprofen | 71 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 13 |
| Eliquis | Apixaban | 67 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 18 |
| Allopurinol | Allopurinol | 54 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 15 |
| Potassium Chloride | Potassium Chloride | 52 | 13 |
| Vraylar | Cariprazine Hcl | 48 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 13 |
| Donepezil Hcl | Donepezil Hcl | 43 | 17 |
| Famotidine | Famotidine | 42 | 17 |
| Glimepiride | Glimepiride | 42 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 25 |
| Azithromycin | Azithromycin | 39 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 16 |
| Temazepam | Temazepam | 38 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 13 |
| Atenolol | Atenolol | 36 | 13 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 15 |
| Levofloxacin | Levofloxacin | 32 | 26 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Valsartan | Valsartan | 29 | 12 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 14 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Baclofen | Baclofen | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Microgestin Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $455.79 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, INCEPTIV, NEXLETOL, Ozempic, VRAYLAR, Veozah, Wegovy, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error